Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,560.00
-85.00 (-1.83%)
At close: Sep 11, 2026

Sinsin Pharmaceutical Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
2,9833,876539.85346.462,240799.33
Cash & Short-Term Investments
2,9833,876539.85346.462,240799.33
Cash Growth
298.57%618.05%55.82%-84.53%180.24%-68.08%
Accounts Receivable
35,66932,80830,60527,97525,77123,237
Other Receivables
2,9392,0612,2292,2161,9531,652
Receivables
38,60834,86932,83330,19127,72424,889
Inventory
21,95819,97616,64315,73314,39010,370
Prepaid Expenses
264.46140.27103.01160.4534.9133.79
Other Current Assets
621.6558.511,374676.95659.08375.07
Total Current Assets
64,43559,42051,49247,10845,04836,467
Property, Plant & Equipment
63,53464,02065,71868,26466,82569,345
Long-Term Investments
6,8177,6526,6493,2703,5593,183
Other Intangible Assets
554.8563.38580.53586.32592.29499.07
Long-Term Accounts Receivable
-0-0-0-0-0
Long-Term Deferred Tax Assets
2,1781,8461,6661,6121,4001,394
Other Long-Term Assets
3,6403,9963,3793,5703,7903,418
Total Assets
141,159137,497129,484124,409121,213114,307

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
7,3245,7917,2567,0606,8154,746
Accrued Expenses
1,4981,424902.13845.07864.38784.18
Short-Term Debt
38,37320,37420,70616,14211,79412,720
Current Portion of Long-Term Debt
84021,93020,79318,38412,6298,590
Current Portion of Leases
110.91127.34170.4776.79132.21116.44
Current Income Taxes Payable
867.51801.32273.84169.82186.45-
Other Current Liabilities
11,3399,9168,9999,0429,9076,962
Total Current Liabilities
60,35360,36359,10151,72042,32733,919
Long-Term Debt
6301,2093,8229,84318,86524,676
Long-Term Leases
121.8955.28115.3659.0161.44133.54
Pension & Post-Retirement Benefits
----115.17198.36
Other Long-Term Liabilities
1,3161,350877.82696.83313.31580.1
Total Liabilities
62,42162,97763,91562,31961,68259,507

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
7,5857,5857,5857,5857,5857,585
Additional Paid-In Capital
10,50614,45014,45014,45014,45014,450
Retained Earnings
62,45353,23644,87541,01937,47832,890
Comprehensive Income & Other
-1,441-442.37-1,037-759.18184.151.31
Total Common Equity
79,10474,82965,87462,29559,69854,927
Minority Interest
-366.35-308.99-304.86-204.62-166.81-126.43
Shareholders' Equity
78,73774,52065,56962,09059,53154,800
Total Liabilities & Equity
141,159137,497129,484124,409121,213114,307

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
40,07643,69545,60644,50543,48146,236
Net Cash (Debt)
-37,093-39,818-45,066-44,158-41,241-45,437
Net Cash Growth
------
Net Cash Per Share
-2442.29-2624.72-2968.47-2910.81-2718.51-2995.06
Filing Date Shares Outstanding
15.1615.1715.1715.1715.1715.17
Total Common Shares Outstanding
15.1615.1715.1715.1715.1715.17
Working Capital
4,082-942.28-7,608-4,6122,7202,548
Book Value Per Share
5216.934932.544342.224106.333935.143620.62
Tangible Book Value
78,54974,26665,29361,70959,10654,428
Tangible Book Value Per Share
5180.344895.404303.954067.683896.093587.73
Land
13,94413,94413,94413,94413,86013,722
Buildings
44,75244,66644,47744,26444,09343,922
Machinery
36,01134,81233,87532,62827,54526,864
Construction In Progress
586.39375.5----